Estland - estisk - Ravimiamet

venus pharma gmbh - tsefuroksiim - süste-/infusioonilahuse pulber - 750mg 1tk

Estland - estisk - Ravimiamet

venus pharma gmbh - tsefuroksiim - süste-/infusioonilahuse pulber - 1,5g 1tk

Estland - estisk - Ravimiamet

venus pharma gmbh - tseftriaksoon - süste-/infusioonilahuse pulber - 2g 10tk; 2g 1tk; 2g 5tk

Estland - estisk - Ravimiamet

venus pharma gmbh - tseftriaksoon - süste-/infusioonilahuse pulber - 1g 1tk; 1g 10tk

Estland - estisk - Ravimiamet

pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk

Estland - estisk - Ravimiamet

pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk

Estland - estisk - Ravimiamet

pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk

Estland - estisk - Ravimiamet

pekana naturheilmittel gmbh - homöopaatilised preparaadid - pillid - 10g 1tk

Estland - estisk - Ravimiamet

pekana naturheilmittel gmbh - homöopaatilised preparaadid - kõrvatilgad, lahus - 10ml 1tk

Den Europæiske Union - estisk - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mitu müeloomit - antineoplastilised ained - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.